Loading...
Replimune Group, Inc.
REPL•NASDAQ
Healthcare
Biotechnology
$3.10
$-0.23(-7.05%)
Replimune Group, Inc. (REPL) Financial Performance & Income Statement Overview
Review Replimune Group, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-32.58%
↓ 32.58%
Net Income Growth
-23.82%
↓ 23.82%
Operating Cash Flow Growth
-44.84%
↓ 44.84%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-57.98%
↓ 57.98%
ROIC
-47.45%
↓ 47.45%
Replimune Group, Inc. (REPL) Income Statement & Financial Overview
Review Replimune Group, Inc.'s (REPL) income statement with detailed quarterly and annual figures.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $4.04M |
| Cost of Revenue | $0.00 | $0.00 | $736000.00 | $655000.00 |
| Gross Profit | $0.00 | $0.00 | -$736000.00 | $3.39M |
| Gross Profit Ratio | $0.00 | $0.00 | $0.84 | |
| R&D Expenses | $48.004M | $43.45M | $42.97M | $42.58M |
| SG&A Expenses | $18.02M | $15.47M | $14.39M | $16.18M |
| Operating Expenses | $66.02M | $58.92M | $56.93M | $58.09M |
| Total Costs & Expenses | $66.02M | $58.92M | $57.37M | $58.09M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $1.98M | $1.97M | $1.96M | $1.95M |
| Depreciation & Amortization | $1.00M | $925000.00 | $736000.00 | $705000.00 |
| EBITDA | -$63.16M | -$50.16M | -$51.51M | -$53.20M |
| EBITDA Ratio | -$13.16 | |||
| Operating Income | -$66.02M | -$58.92M | -$57.37M | -$58.76M |
| Operating Income Ratio | -$14.54 | |||
| Other Income/Expenses (Net) | $254000.00 | $5.86M | $3.60M | $3.62M |
| Income Before Tax | -$65.77M | -$53.05M | -$53.77M | -$55.14M |
| Income Before Tax Ratio | -$13.64 | |||
| Income Tax Expense | $575000.00 | $0.00 | $0.00 | -$65000.00 |
| Net Income | -$66.34M | -$53.05M | -$53.77M | -$55.08M |
| Net Income Ratio | -$13.63 | |||
| EPS | -$0.79 | -$0.68 | -$0.78 | -$0.90 |
| Diluted EPS | -$0.79 | -$0.68 | -$0.78 | -$0.90 |
| Weighted Avg Shares Outstanding | $83.50M | $78.57M | $69.19M | $61.42M |
| Weighted Avg Shares Outstanding (Diluted) | $83.50M | $78.57M | $69.19M | $61.42M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan